TY - JOUR
T1 - Relapsed acute myeloid leukemia
T2 - Why is there no standard of care?
AU - Ravandi, Farhad
N1 - Funding Information:
Farhad Ravandi has received research funding from Sunesis, Merck, Celgene, Bristol Myers Squibb, and Novartis and has received honoraria from Bayer/Onyx, Sunesis, Teva, Seattle Genetics, Pfizer, Amgen, Incyte, and Boehringer Ingelheim for participation in advisory meetings or CME events.
PY - 2013/9
Y1 - 2013/9
N2 - Relapse after achieving a prior response remains one of the most important obstacles to improving the outcome of patients with acute myeloid leukemia (AML). Although overall, the majority of patients with disease relapse do poorly, this is by no means uniform and a number of predictors of outcome have been identified. Previously, most trials of investigational agents in the setting of disease relapse in AML have accrued a wide range of patients with widely different patient and disease characteristics. With increased understanding of the biology of the neoplastic change in AML, and better identification of disease subsets based on their molecular characterization, target-specific novel agents are being developed that will hopefully lead to better strategies, not only for treating relapsed disease, but also for the initial induction treatment.
AB - Relapse after achieving a prior response remains one of the most important obstacles to improving the outcome of patients with acute myeloid leukemia (AML). Although overall, the majority of patients with disease relapse do poorly, this is by no means uniform and a number of predictors of outcome have been identified. Previously, most trials of investigational agents in the setting of disease relapse in AML have accrued a wide range of patients with widely different patient and disease characteristics. With increased understanding of the biology of the neoplastic change in AML, and better identification of disease subsets based on their molecular characterization, target-specific novel agents are being developed that will hopefully lead to better strategies, not only for treating relapsed disease, but also for the initial induction treatment.
KW - acute myeloid leukemia
KW - biology
KW - relapse
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84889664310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889664310&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2013.10.005
DO - 10.1016/j.beha.2013.10.005
M3 - Review article
C2 - 24309527
AN - SCOPUS:84889664310
SN - 1521-6926
VL - 26
SP - 253
EP - 259
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 3
ER -